The aim is to explore pyrazole–triazole hybrids as effective inhibitors for several kinases involved in cancer progression.
Investigated the chemical properties of pyrazole–triazole hybrids.
Evaluated their effectiveness as multi-target kinase inhibitors.
Assessed the potential synergistic effects in cancer therapies.
Identified specific pyrazole–triazole compounds that inhibit multiple kinases.
Showed these hybrids enhance anticancer efficacy compared to single-target treatments.
Demonstrated potential to overcome drug resistance in cancer cells.
Abstract
The ongoing issue of drug resistance and the lack of specificity in existing cancer treatments highlight the necessity for innovative multi-target agents.